Key takeaways
Anoro Ellipta (umeclidinium/vilanterol) and Symbicort (budesonide/formoterol) are both inhalers used to manage chronic obstructive pulmonary disease (COPD), but they have some key differences. Anoro Ellipta combines a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA), while Symbicort combines a corticosteroid and a LABA. Anoro Ellipta is taken once daily, whereas Symbicort is taken twice daily. Symbicort is also approved for treating asthma, unlike Anoro Ellipta. Anoro Ellipta does not have a generic version, making it potentially more expensive, while Symbicort is available in generic forms. Additionally, Anoro Ellipta does not require mouth rinsing after use, but Symbicort does to prevent thrush. Both medications are not suitable for sudden breathing problems and should be used as long-term maintenance treatments.
Prices with our coupons for Anoro Ellipta vs. Symbicort
